About Genomenon
Genomenon is a company based in Ann Arbor (United States) founded in 2014.. Genomenon has raised $36.84 million across 13 funding rounds from investors including NIH, University of Michigan and HHS. Genomenon has completed 1 acquisition, including Boston Genetics. Genomenon offers products and services including Mastermind, Cancer Knowledgebase, and Curation Services. Genomenon operates in a competitive market with competitors including Human Longevity, Denali Therapeutics, DNAnexus, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter Ann Arbor, United States
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genomenon, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$36.84 M (USD)
in 13 rounds
-
Latest Funding Round
$5.46 M (USD), Series B
May 01, 2024
-
Investors
NIH
& 18 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genomenon
Genomenon offers a comprehensive portfolio of products and services, including Mastermind, Cancer Knowledgebase, and Curation Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI tool for analyzing and interpreting genomic datasets.
Platform connecting cancer variants to therapies and trials.
Expert services for variant classification and analysis.
Unlock access to complete
Unlock access to complete
Funding Insights of Genomenon
Genomenon has successfully raised a total of $36.84M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $5.46 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series B — $5.5M
-
First Round
First Round
(14 Aug 2015)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series B - Genomenon | Valuation |
investors |
|
| Mar, 2022 | Amount | Series B - Genomenon | Valuation | Beringea , Spring Mountain Capital | |
| Feb, 2022 | Amount | Grant - Genomenon | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genomenon
Genomenon has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, University of Michigan and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in growth-stage startups by Beringea.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Early-stage venture capital investments are made in medical startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genomenon
Genomenon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Boston Genetics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapy-based drug development services are provided.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Genomenon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genomenon Comparisons
Competitors of Genomenon
Genomenon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Human Longevity, Denali Therapeutics, DNAnexus, Poseida Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genomics data and cell therapy-based diagnostic and therapeutic solutions
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Cloud-based genome informatics and data management are provided.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genomenon
Frequently Asked Questions about Genomenon
When was Genomenon founded?
Genomenon was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Genomenon located?
Genomenon is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Is Genomenon a funded company?
Genomenon is a funded company, having raised a total of $36.84M across 13 funding rounds to date. The company's 1st funding round was a Grant of $1.7M, raised on Aug 14, 2015.
What does Genomenon do?
Genomenon was founded in 2014 in Ann Arbor, United States, within the bioinformatics sector. AI-driven tools and a comprehensive meta-database of genomic variants are provided for genomic analysis. MASTERMIND organizes variants into clinical categories based on disease associations determined by automated algorithms. SAVANT identifies actionable genetic variants from gene panels, exomes, or patient genomes. PRODIGY analyzes multi-sample datasets to pinpoint disease-causing variants for research purposes.
Who are the top competitors of Genomenon?
Genomenon's top competitors include DNAnexus, Juno Therapeutics and Human Longevity.
What products or services does Genomenon offer?
Genomenon offers Mastermind, Cancer Knowledgebase, and Curation Services.
How many acquisitions has Genomenon made?
Genomenon has made 1 acquisition, including Boston Genetics.
Who are Genomenon's investors?
Genomenon has 19 investors. Key investors include NIH, University of Michigan, HHS, Broadoak Capital Partners, and IrishAngels.